目的 探討舍雷肽酶腸溶片聯(lián)合噻托溴銨粉吸入劑治療支氣管擴(kuò)張癥的臨床療效。方法 對(duì)2015年9月-2016年9月在延安大學(xué)附屬醫(yī)院接受治療的86例支氣管擴(kuò)張癥患者臨床資料進(jìn)行回顧性分析，根據(jù)治療方案的差別分為治療組和對(duì)照組，每組各43例。對(duì)照組用吸入器吸入噻托溴銨粉吸入劑，18 μg/次，1次/d。治療組在對(duì)照組基礎(chǔ)上口服舍雷肽酶腸溶片，1片/次，3次/d。兩組患者均連續(xù)治療7 d。觀察兩組的臨床療效，比較兩組治療前后咳嗽程度評(píng)分、咳痰量評(píng)分、肺部啰音評(píng)分、第一秒用力呼氣容積（FEV1）、用力肺活量（FVC）、最大呼氣流速（PEF）的變化情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為81.40%、97.67%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者咳嗽程度評(píng)分、咳痰量評(píng)分、肺部啰音評(píng)分均顯著降低，F(xiàn)EV1、FVC、PEF均顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后治療組咳嗽程度評(píng)分、咳痰量評(píng)分、肺部啰音評(píng)分低于對(duì)照組，F(xiàn)EV1、FVC、PEF高于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 舍雷肽酶腸溶片聯(lián)合噻托溴銨粉吸入劑治療支氣管擴(kuò)張癥具有較好的臨床療效，可明顯改善患者的臨床癥狀和肺功能，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To evaluate the clinical efficacy of Serrapeptase Enteric-coated Tablets combined with tiotropium bromide in treatment of bronchiectasis. Methods The clinical data of 86 patients with bronchiectasis who were treated in Yan'an University Affiliated Hospital from September 2015 to September 2016 were retrospectively analyzed. They were divided into the control and treatment groups based on different treatment, and each group had 43 cases. The patients in the control group were inhalated Tiotropium Bromide Powder for inhalation with inhaler suction, 18 μg/time, once daily. The patients in the treatment group were po administered with Serrapeptase Enteric-coated Tablets on the basis of the control group, 1 tablet/time, three times daily. The patients in two groups were treated for 7 d. After treatment, the efficacy was evaluated, and the changes of cough degree score, sputum volume score, lung rale score, FEV1, FVC, and PEF in two groups before and after treatment were compared. Results After treatment, the efficacies in the control and treatment groups were 81.40% and 97.67%, respectively, and there were differences between two groups (P<0.05). After treatment, cough degree score, sputum volume score, and lung rale score in the two groups were significantly decreased, and FEV1, FVC, and PEF were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, cough degree score, sputum volume score, and lung rale score in the treatment group were lower than those in the control group, and FEV1, FVC, and PEF in the treatment group were higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Serrapeptase Enteric-coated Tablets combined with tiotropium bromide has clinical curative effect in treatment of bronchiectasis, and can obviously improve the clinical symptoms and lung function, which has a certain clinical application value.